Evidence map›Paper›PMID 39033024›Full record

ArticleGut2024

Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis.

Henriette Kreimeyer, Carlos G Gonzalez, Marcos F Fondevila, Cynthia L Hsu, Phillipp Hartmann, Xinlian Zhang, Peter Stärkel, Francisco Bosques-Padilla, Elizabeth C Verna, Juan G Abraldes and 13 more

Abstract readMulticenter Study
In one paragraph

Article in Gut, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Henriette KreimeyerDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Carlos G GonzalezDepartment of Pharmacology, University of California San Diego, La Jolla, California, USA.
Marcos F FondevilaDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Cynthia L HsuDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Phillipp HartmannDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA.
Xinlian ZhangDivision of Biostatistics and Bioinformatics, Herbert Wertehim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, USA.
Peter StärkelDepartment of Hepatology and Gastroenterology, Cliniques Universitaires Saint Luc, Brussels, Belgium.
Francisco Bosques-PadillaHospital Universitario, Departamento de Gastroenterología, Universidad Autónoma de Nuevo León, Monterrey, Mexico.ORCID 0000-0002-9795-7209
Elizabeth C VernaDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Juan G AbraldesDivision of Gastroenterology (Liver Unit), University of Alberta, Edmonton, Alberta, Canada.
Robert S BrownDivision of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA.
Victor VargasLiver Unit, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Jose AltamiranoLiver Unit, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Juan CaballeríaCentro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
Debbie L ShawcrossInstitute of Liver Studies, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King's College London, London, UK.ORCID 0000-0001-6133-4619
Alexandre LouvetService des Maladies de L'appareil Digestif et Unité INFINITE 1286, Hôpital Huriez, Lille, France.ORCID 0000-0002-5293-007X
Michael R LuceyDivision of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Philippe MathurinService des Maladies de L'appareil Digestif et Unité INFINITE 1286, Hôpital Huriez, Lille, France.ORCID 0000-0002-8110-2898
Guadalupe Garcia-TsaoSection of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA.
Ramón BatallerLiver Unit, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
AlcHepNet InvestigatorsRoster for authorship, listed in Collaborators.
David J GonzalezDepartment of Pharmacology, University of California San Diego, La Jolla, California, USA.
Bernd SchnablDepartment of Medicine, University of California San Diego, La Jolla, California, USA beschnabl@ucsd.edu.ORCID 0000-0002-6281-825X

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HIDEKAZU TSUKAMOTO · 1999 to 2026
$45.8M
UCSD/SDSU IRACDAK12GM068524 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2003 to 2025
$24.4M
UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2019 to 2026
$10.8M
Training Grant in GastroenterologyT32DK007202 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 1985 to 2022
$7.7M
The Role of the Intestinal Mycobiome in Alcoholic Liver DiseaseR01AA024726 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2018 to 2026
$3.9M
Microbiome and intestinal innate immune response in alcoholic liver diseaseR01AA020703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHNABL, BERND G. · 2011 to 2020
$3.6M
Microbiome and Intestinal Innate Immune Response in Alcoholic Liver DiseaseR37AA020703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2021 to 2026
$2.5M
Developing Diverse Physician-Investigator Leaders for the Future of Child HealthK12HD105271 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Gabriel G Haddad · 2021 to 2026
$1.8M
Microbiome as therapeutic target in alcoholic hepatitisU01AA026939 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FOUTS, DERRICK E, SCHNABL, BERND G. · 2018 to 2022
$1.7M
Liver-enriched Transcription Factors as Prognostic Markers and Therapeutic Targets in Alcoholic HepatitisU01AA026972 · NIAAA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ARTEEL, GAVIN E · 2018 to 2022
$1.2M
BLRD VA I01 BX004594NCATS NIH HHS KL2 TR001444NCATS NIH HHS UL1 TR001863NIAAA NIH HHS K99 AA031328NIAAA NIH HHS P50 AA011999NIAAA NIH HHS R01 AA020703NIAAA NIH HHS R01 AA024726NIAAA NIH HHS R37 AA020703NIAAA NIH HHS U01 AA026939NIAAA NIH HHS U01 AA026972NICHD NIH HHS K12 HD105271NIDDK NIH HHS P30 DK120515NIDDK NIH HHS T32 DK007202NIGMS NIH HHS K12 GM068524
6 · The paper itself

Abstract

objectivePatients with alcohol-associated hepatitis (AH) have a high mortality. Alcohol exacerbates liver damage by inducing gut dysbiosis, bacterial translocation and inflammation, which is characterised by increased numbers of circulating and hepatic neutrophils.

designIn this study, we performed tandem mass tag (TMT) proteomics to analyse proteins in the faeces of controls (n=19), patients with alcohol-use disorder (AUD; n=20) and AH (n=80) from a multicentre cohort (InTeam). To identify protein groups that are disproportionately represented, we conducted over-representation analysis using Reactome pathway analysis and Gene Ontology to determine the proteins with the most significant impact. A faecal biomarker and its prognostic effect were validated by ELISA in faecal samples from patients with AH (n=70), who were recruited in a second and independent multicentre cohort (AlcHepNet).

resultFaecal proteomic profiles were overall significantly different between controls, patients with AUD and AH (principal component analysis p=0.001, dissimilarity index calculated by the method of Bray-Curtis). Proteins that showed notable differences across all three groups and displayed a progressive increase in accordance with the severity of alcohol-associated liver disease were predominantly those located in neutrophil granules. Over-representation and Reactome analyses confirmed that differentially regulated proteins are part of granules in neutrophils and the neutrophil degranulation pathway. Myeloperoxidase (MPO), the marker protein of neutrophil granules, correlates with disease severity and predicts 60-day mortality. Using an independent validation cohort, we confirmed that faecal MPO levels can predict short-term survival at 60 days.

conclusionsWe found an increased abundance of faecal proteins linked to neutrophil degranulation in patients with AH, which is predictive of short-term survival and could serve as a prognostic non-invasive marker.

Indexed as

BiomarkersCell DegranulationFecesHepatitis, AlcoholicNeutrophilsProteomicsAdultCase-Control StudiesFemaleHumansMaleMiddle AgedPrognosisBiomarkersALCOHOLIC LIVER DISEASEALCOHOL-INDUCED INJURY

Identifiers

PMID39033024
PMCPMC11631684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.